[Empagliflozin: 当前适应症和日常临床实践方面]。

IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Giornale italiano di cardiologia Pub Date : 2023-12-01 DOI:10.1714/4181.41696

Massimo Iacoviello, Nadia Aspromonte

{"title":"[Empagliflozin: 当前适应症和日常临床实践方面]。","authors":"Massimo Iacoviello, Nadia Aspromonte","doi":"10.1714/4181.41696","DOIUrl":null,"url":null,"abstract":"Empagliflozin is one of the drugs belonging to the class of sodium-glucose cotransporter 2 inhibitors that inhibit the reabsorption of sodium and glucose, at the level of the proximal renal convoluted tubule. The \"serendipity\" of empagliflozin was based on its unexpected beneficial effects in diabetic patients and then in patients affected by heart failure and/or chronic kidney disease regardless of the presence of diabetes. The aim of this review is to offer a complete update on the body of evidence on empagliflozin in heart failure, and also to provide a useful tool in daily clinical practice.","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":"24 12","pages":"3S-12S"},"PeriodicalIF":0.7000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Empagliflozin: current indications and aspects for daily clinical practice].\",\"authors\":\"Massimo Iacoviello, Nadia Aspromonte\",\"doi\":\"10.1714/4181.41696\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Empagliflozin is one of the drugs belonging to the class of sodium-glucose cotransporter 2 inhibitors that inhibit the reabsorption of sodium and glucose, at the level of the proximal renal convoluted tubule. The \\\"serendipity\\\" of empagliflozin was based on its unexpected beneficial effects in diabetic patients and then in patients affected by heart failure and/or chronic kidney disease regardless of the presence of diabetes. The aim of this review is to offer a complete update on the body of evidence on empagliflozin in heart failure, and also to provide a useful tool in daily clinical practice.\",\"PeriodicalId\":12510,\"journal\":{\"name\":\"Giornale italiano di cardiologia\",\"volume\":\"24 12\",\"pages\":\"3S-12S\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Giornale italiano di cardiologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1714/4181.41696\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Giornale italiano di cardiologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1714/4181.41696","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

Empagliflozin 属于钠-葡萄糖共转运体 2 抑制剂，可抑制近端肾曲小管对钠和葡萄糖的重吸收。empagliflozin的 "偶然性 "是基于其对糖尿病患者以及受心力衰竭和/或慢性肾病影响的患者（无论是否患有糖尿病）出乎意料的有益作用。本综述旨在全面更新有关安格列酮治疗心力衰竭的证据，并为日常临床实践提供有用的工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Empagliflozin: current indications and aspects for daily clinical practice].

Empagliflozin is one of the drugs belonging to the class of sodium-glucose cotransporter 2 inhibitors that inhibit the reabsorption of sodium and glucose, at the level of the proximal renal convoluted tubule. The "serendipity" of empagliflozin was based on its unexpected beneficial effects in diabetic patients and then in patients affected by heart failure and/or chronic kidney disease regardless of the presence of diabetes. The aim of this review is to offer a complete update on the body of evidence on empagliflozin in heart failure, and also to provide a useful tool in daily clinical practice.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Giornale italiano di cardiologia CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

1.10

自引率

0.00%

发文量